BRAF V600E-mutated lung adenocarcinoma with thyroid metastasis as the initial manifestation: a case report
Thyroid metastasis of lung adenocarcinoma is exceedingly uncommon. Here we present a case of a 72-year-old Chinese male with hoarseness, dysphagia, pain, and palpable thyroid nodules. Ultrasonography-guided thyroid fine-needle aspiration cytology (FNAC) suggested a high-grade follicular-derived thyr...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1468233/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087339049943040 |
|---|---|
| author | Yufei Liu Yufei Liu Hanhan Lei Hanhan Lei Lingling Cai Lingling Cai Yuyan Tan Xinyu Song |
| author_facet | Yufei Liu Yufei Liu Hanhan Lei Hanhan Lei Lingling Cai Lingling Cai Yuyan Tan Xinyu Song |
| author_sort | Yufei Liu |
| collection | DOAJ |
| description | Thyroid metastasis of lung adenocarcinoma is exceedingly uncommon. Here we present a case of a 72-year-old Chinese male with hoarseness, dysphagia, pain, and palpable thyroid nodules. Ultrasonography-guided thyroid fine-needle aspiration cytology (FNAC) suggested a high-grade follicular-derived thyroid carcinoma (HGFCTC). Molecular analysis identified a BRAF V600E mutation. Comprehensive histopathological and immunohistochemical examinations, however, revealed that the thyroid cancer originated from the left lung. The patient received a 6-month post-operative dual-target therapy with dalafenib and trametinib. As of the last follow-up, the patient was still alive, demonstrating the effectiveness of targeted therapy. |
| format | Article |
| id | doaj-art-409bda4be505446198360f536ceb2273 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-409bda4be505446198360f536ceb22732025-02-06T05:21:51ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-02-011510.3389/fonc.2025.14682331468233BRAF V600E-mutated lung adenocarcinoma with thyroid metastasis as the initial manifestation: a case reportYufei Liu0Yufei Liu1Hanhan Lei2Hanhan Lei3Lingling Cai4Lingling Cai5Yuyan Tan6Xinyu Song7Institute of Pathology, China Three Gorges University, Yichang, ChinaDepartment of Pathology, Yichang Central People’s Hospital, Yichang, Hubei, ChinaInstitute of Pathology, China Three Gorges University, Yichang, ChinaDepartment of Pathology, Yichang Central People’s Hospital, Yichang, Hubei, ChinaInstitute of Pathology, China Three Gorges University, Yichang, ChinaDepartment of Pathology, Yichang Central People’s Hospital, Yichang, Hubei, ChinaDepartment of Thyroid and breast Surgery, Yichang Central People’s Hospital, Yichang, ChinaDepartment of Respiratory and Critical Care Medicine, Yichang Central People’s Hospital, Yichang, ChinaThyroid metastasis of lung adenocarcinoma is exceedingly uncommon. Here we present a case of a 72-year-old Chinese male with hoarseness, dysphagia, pain, and palpable thyroid nodules. Ultrasonography-guided thyroid fine-needle aspiration cytology (FNAC) suggested a high-grade follicular-derived thyroid carcinoma (HGFCTC). Molecular analysis identified a BRAF V600E mutation. Comprehensive histopathological and immunohistochemical examinations, however, revealed that the thyroid cancer originated from the left lung. The patient received a 6-month post-operative dual-target therapy with dalafenib and trametinib. As of the last follow-up, the patient was still alive, demonstrating the effectiveness of targeted therapy.https://www.frontiersin.org/articles/10.3389/fonc.2025.1468233/fullnon-small cell lung cancer (NSCLC)BRAF V600E mutationimmunohistochemistrythyroidmetastasis |
| spellingShingle | Yufei Liu Yufei Liu Hanhan Lei Hanhan Lei Lingling Cai Lingling Cai Yuyan Tan Xinyu Song BRAF V600E-mutated lung adenocarcinoma with thyroid metastasis as the initial manifestation: a case report Frontiers in Oncology non-small cell lung cancer (NSCLC) BRAF V600E mutation immunohistochemistry thyroid metastasis |
| title | BRAF V600E-mutated lung adenocarcinoma with thyroid metastasis as the initial manifestation: a case report |
| title_full | BRAF V600E-mutated lung adenocarcinoma with thyroid metastasis as the initial manifestation: a case report |
| title_fullStr | BRAF V600E-mutated lung adenocarcinoma with thyroid metastasis as the initial manifestation: a case report |
| title_full_unstemmed | BRAF V600E-mutated lung adenocarcinoma with thyroid metastasis as the initial manifestation: a case report |
| title_short | BRAF V600E-mutated lung adenocarcinoma with thyroid metastasis as the initial manifestation: a case report |
| title_sort | braf v600e mutated lung adenocarcinoma with thyroid metastasis as the initial manifestation a case report |
| topic | non-small cell lung cancer (NSCLC) BRAF V600E mutation immunohistochemistry thyroid metastasis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1468233/full |
| work_keys_str_mv | AT yufeiliu brafv600emutatedlungadenocarcinomawiththyroidmetastasisastheinitialmanifestationacasereport AT yufeiliu brafv600emutatedlungadenocarcinomawiththyroidmetastasisastheinitialmanifestationacasereport AT hanhanlei brafv600emutatedlungadenocarcinomawiththyroidmetastasisastheinitialmanifestationacasereport AT hanhanlei brafv600emutatedlungadenocarcinomawiththyroidmetastasisastheinitialmanifestationacasereport AT linglingcai brafv600emutatedlungadenocarcinomawiththyroidmetastasisastheinitialmanifestationacasereport AT linglingcai brafv600emutatedlungadenocarcinomawiththyroidmetastasisastheinitialmanifestationacasereport AT yuyantan brafv600emutatedlungadenocarcinomawiththyroidmetastasisastheinitialmanifestationacasereport AT xinyusong brafv600emutatedlungadenocarcinomawiththyroidmetastasisastheinitialmanifestationacasereport |